- Conditions
- Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
- Interventions
- Tarlatamab, Durvalumab, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 50
- States / cities
- Casa Grande, Arizona • Goodyear, Arizona • Hot Springs, Arkansas + 45 more
Location Directory
Clinical trials in Phoenix, Arizona
This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8158
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 997–1008 of 8,158 matching trials in Phoenix, AZ.
Live ClinicalTrials.gov results.
Institutions in Phoenix
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
- Conditions
- Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
- Interventions
- Belimumab, Placebo
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
- Conditions
- Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
- Conditions
- Parenting, Mental Health Wellness 1, Substance Use, Risky Health Behavior
- Interventions
- Parenting in 2 Worlds (P2W), Healthy Families in 2 Worlds (HF2W)
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Denver, Colorado • Saint Paul, Minnesota + 1 more
- Conditions
- Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
- Interventions
- Aerobic Exercise Training, Health Education (Active comparator)
- Behavioral · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
- Interventions
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 170
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
- Conditions
- Asthma
- Interventions
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 70
- States / cities
- Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Parkinson's Disease
- Interventions
- Lab Assay for seven genetic variants for Parkinson's Disease
- Device
- Lead sponsor
- Parkinson's Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35,382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 50 more
- Conditions
- Episodic Migraine
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 58 more
- Conditions
- Coccidioidomycosis, Blastomycosis, Histoplasmosis, Dimorphic Fungal Infection, Endemic Mycoses
- Interventions
- Oteseconazole
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Davis, California + 1 more
- Conditions
- Fibromyalgia
- Interventions
- AXS-14 (Esreboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more